<tbody id="ff6si"><div id="ff6si"></div></tbody>
  • <track id="ff6si"></track>

    1. <option id="ff6si"></option>

    2. <option id="ff6si"></option>
      1. <track id="ff6si"></track>

          Fresenius Group Overview

          Results Center

          To archive

          Q2/19 Results

          Fresenius raises Group sales growth guidance after good second quarter
          • Good organic sales growth across all business segments
          • Growth investments well on track
          • Fresenius Kabi successfully launched first biosimilar in Europe; continued excellent growth in Emerging Markets
          • Fresenius Helios showing strong organic sales growth in Germany and enters successfully Colombian hospital market
          • Fresenius Medical Care’s strategy reinforced by U.S. government’s plans for changes of kidney disease care

          Selected Key Figures Q2/19

          key figures Q2 19

          1 On a comparable basis

          2 In constant currency

          3 Net income attributable to shareholders of Fresenius SE & Co. KGaA